文献速递瓣膜外科

生物瓣结构衰败后再次主动脉瓣置换与初次手术的比较

Redo surgical aortic valve replacement for bioprosthetic structural valve deterioration.
PubMed 文献 · Eur J Cardiothorac Surg · 2024-01-01

该回顾性研究比较了因生物瓣结构衰败行再次孤立性主动脉瓣置换术(rSAVR)与初次孤立性主动脉瓣置换术(SAVR)的临床结局,共纳入2620例患者,其中rSAVR 174例(6.6%)。单因素分析显示初次SAVR的全因死亡和死亡或卒中发生率更低(0.5% vs 5.8%,2.2% vs 6.9%,P<0.001),但多因素分析中既往手术与不良结局无关;匹配比较322例患者后,两组死亡或卒中率无差异(均为4.8%,P=1.0)。结论认为rSAVR增加的风险多可归因于合并症,择期rSAVR的结局与初次SAVR相似。

要点

  • 单因素分析中rSAVR的院内全因死亡和死亡或卒中率高于初次SAVR,但多因素分析中既往手术并非独立危险因素。
  • 匹配比较显示rSAVR与初次SAVR的死亡或卒中率无显著差异(均为4.8%,P=1.0)。
  • 择期rSAVR患者可预期与初次SAVR相似的结局。

核心结论

  • 单因素分析中因结构衰败行再次手术与较高的早期死亡和卒中率相关,但该风险大部分可归因于合并症。
  • 择期rSAVR的结局与初次SAVR相似。

研究设计与样本

  • 共纳入2620例患者,女性占39.5%,EuroSCORE II中位数1.7(IQR 1.1-2.7),其中rSAVR 174例(6.6%)。
  • 主要结局为住院期间全因死亡或卒中;次要结局包括心肌梗死、因出血再次探查和永久起搏器植入。

主要发现

  • 初次SAVR组患者年龄更大(69 vs 67岁,P=0.001),既往卒中史比例更低(0.9% vs 4.0%,P=0.003)。
  • 初次SAVR组全因死亡发生率更低(0.5% vs 5.8%),死亡或卒中发生率也更低(2.2% vs 6.9%),P<0.001。
  • 多因素分析中既往手术与不良临床结局无关。
  • 匹配比较322例患者,rSAVR与SAVR的死亡或卒中率无差异(均为4.8%,P=1.0)。

临床怎么用

  • 择期rSAVR患者可预期与初次SAVR相似的结局。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare isolated primary bioprosthetic surgical aortic valve replacement (SAVR) with isolated redo surgical aortic valve replacement (rSAVR) due to structural valve deterioration (SVD). METHODS: Clinical data of consecutive patients who underwent primary isolated SAVR and isolated rSAVR due to SVD between 1 January 2011 and 31 December 2022, at Leipzig Heart Center were retrospectively compared with regard to the primary outcome of all-cause mortality or stroke during hospitalization. Secondary outcomes of interest included myocardial infarction, re-exploration for bleeding, and permanent pacemaker implantation. RESULTS: A total of 2620 patients, 39.5% females, with a median EuroSCORE II of 1.7 [interquartile range (IQR) 1.1-2.7] were identified, of which rSAVR was performed in 174 patients (6.6%). Patients undergoing primary SAVR were older (69 vs 67 years of age, P = 0.001) and were less likely to have a history of prior stroke (0.9% vs 4.0%, P = 0.003). Although both all-cause death and death or stroke occurred less often following primary SAVR (0.5% vs 5.8%, and 2.2% vs 6.9%, respectively; P < 0.001), prior surgery was not associated with adverse clinical outcome in multivariable analysis. In a matched comparison of 322 patients, rates of death or stroke did not differ between groups (4.8% for both rSAVR and SAVR, P = 1.0). CONCLUSIONS: Although redo surgery for SVD is associated with increased rates of early mortality and stroke by univariate analysis, much of this increased risk can be accounted for by comorbidities. Patients undergoing rSAVR on an elective basis can expect an outcome similar to that of primary SAVR.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Raschpichler M, Kiefer P, Otto W, et al. Redo surgical aortic valve replacement for bioprosthetic structural valve deterioration. Eur J Cardiothorac Surg. 2024. PMID: 39340801. doi:10.1093/ejcts/ezae353

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。